Every 10-Q that Pacira BioSciences, Inc. (PCRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PCRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCRX filings page.
Pacira BioSciences, Inc. reported Q2 2026 total revenues of $192,399 (in thousands), mainly from EXPAREL and ZILRETTA, with net income of $4,653 (in thousands) or $0.12 per diluted share, compared with a net loss a year earlier. Results included a $6.4 million discrete tax benefit from reversing a U.K. valuation allowance.
The company agreed to divest its iovera° cryoanalgesia business to Zimmer for up to $140.0 million, including a $70.0 million upfront payment and up to $70.0 million in revenue-based milestones; the deal closed on July 31, 2026, with $73.6 million cash received after adjustments. Cash and cash equivalents rose to $205,875 (in thousands), supported by $83,140 (in thousands) of operating cash flow, while Pacira repurchased $50,448 (in thousands) of stock and repaid $10,000 (in thousands) on its Revolving Credit Facility, ending the quarter with total debt of $363,124 (in thousands).
Pacira BioSciences, Inc. reported net product sales of $177.4M for the quarter ended March 31, 2026, up from $167.6M a year earlier, driven mainly by EXPAREL and ZILRETTA. Net income was $2.9M, down from $4.8M, as higher operating expenses and lower other income offset revenue growth.
EXPAREL generated $143.3M in sales, ZILRETTA $26.8M, iovera° $6.2M and veterinary bupivacaine liposome injectable suspension $1.2M. Operating cash flow was $25.7M, with cash and cash equivalents of $144.3M and total debt of $367.7M, including $281.7M of 2.125% convertible notes due 2029.
The company repurchased 2.24 million shares for $50.4M under its $300M authorization, leaving $100M available, and ended the period with 39.35 million common shares outstanding. Pacira continues to focus on its non-opioid pain portfolio, led by EXPAREL, ZILRETTA, and iovera°, while advancing pipeline programs such as gene therapy candidate PCRX-201.
Pacira BioSciences reported quarterly results for the period ended September 30, 2025. Total revenues were $179.5 million, up from $168.6 million a year ago, driven by net product sales of $178.0 million. EXPAREL led with $139.9 million, followed by ZILRETTA at $29.0 million and iovera° at $6.5 million.
The company posted net income of $5.4 million versus a prior-year loss that included a goodwill impairment. Operating expenses fell sharply year over year, with no goodwill impairment this quarter but including a $25.9 million impairment to indefinite‑lived IPR&D tied to ZILRETTA shoulder OA. Nine‑month cash from operations was $108.3 million.
Pacira reshaped its balance sheet: it repaid $202.5 million of 2025 convertible notes at maturity, terminated its Term Loan A, and established a $300.0 million revolving credit facility, with $96.0 million outstanding at quarter‑end. Cash and cash equivalents were $147.6 million and short‑term investments $98.7 million. The company also repurchased $50.0 million of stock in the quarter, bringing year‑to‑date repurchases to $100.4 million; shares outstanding were 42,965,902 as of September 30, 2025.